{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-016857","form_type":"8-K","ticker":"LENZ","cik":"0001815776","company_name":"LENZ Therapeutics, Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.171219+00:00","generated_at":"2026-06-24T01:02:15.576511+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Graphite Bio doses first SCD patient with nula-cel; Q2 net loss $25.9M, cash $328.3M","bullets":["Dosed first patient in Phase 1/2 CEDAR trial of nula-cel for sickle cell disease; initial proof-of-concept data expected mid-2023.","Cash, cash equivalents and marketable securities of $328.3M as of June 30, 2022; cash runway into Q4 2024.","Q2 2022 net loss of $25.9M ($0.48 per share); R&D expenses $17.8M, G&A $9.0M.","Nula-cel received FDA Fast Track designation for SCD; also has Orphan Drug designation.","Preclinical data for GPH102 in beta-thalassemia presented at ASGCT; IND planned by mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-016857","json":"https://secwatch.observer/filing/0000950170-22-016857.json","markdown":"https://secwatch.observer/filing/0000950170-22-016857.md","text":"https://secwatch.observer/filing/0000950170-22-016857.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815776/000095017022016857/0000950170-22-016857-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815776/000095017022016857/grph-20220811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:02:15.576511+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}